Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Business Improves for Local Government-managed Hospitals
January 14, 2002
- 6 Products Including Flutide 200 Diskus Added to NHI List
January 14, 2002
- 9 Wholesalers Accept FTC Recommendation: Cartel Affair in Tohoku
January 14, 2002
- LDP to Review Operations of Univ., Social Insurance Hospitals
January 14, 2002
- OPSR, PMDEC to Be Merged: Administrative Reform
January 14, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 14, 2002
- IFN to Be Re-priced Next April
January 14, 2002
- Suntory, Sankyo Codevelop Glucagon-like Peptide-1 as Antidiabetic
January 14, 2002
- Ceiling of Copayment for the Elderly Decided
January 14, 2002
- Standard Format for Package Inserts for Medical Devices Issued
January 14, 2002
- Social Security Benefits Up 4.0% to \75.04 Trillion
January 14, 2002
- Sumitomo Signs Contract on GPCR Database with LifeSpan
January 14, 2002
- Sanofi-Synthelabo to Consider Independent Marketing: Mr Fauchet
January 14, 2002
- BULLETIN
January 14, 2002
- REGULATORY NEWS IN BRIEF
January 14, 2002
- WORLD NEWS IN BRIEF
January 14, 2002
- Lipitor Shows Highest Growth in Sales: Top 100 Drugs
January 14, 2002
- DIAGNOSTIC NEWS IN BRIEF
January 14, 2002
- Otsuka Licenses Drug for Vitreous Body Hemorrhage from ISTA
January 14, 2002
- OTC NEWS IN BRIEF
January 14, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…